Hypoxia-induced MFAP5 Promotes Tumor Migration and Invasion Via AKT Pathway in Head and Neck Squamous Cell Carcinoma
Affiliations
: Microfibrillar-associated protein 5 (MFAP5) is highly expressed in many types of cancers. Our previous study has observed that overexpression of MFAP5 was correlated with lymph nodes metastasis and poor prognosis in head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism is poorly understood. : The MFAP5 expression is detected under hypoxia condition. HNSCC cell lines are transfected with MFAP5-expressing lentivirus vector to establish stable overexpression model. Wound-healing, migration and invasion assay are used to determine the effect of MFAP5 on HNSCC and metastasis-related proteins are examined by Western blot. lung metastasis assays are conducted by the tail vein injection. In addition, immunohistochemistry is applied to analyze the correlation of MFAP5, hypoxia-induced factor-1 α (HIF-1α), and vimentin in 84 HNSCC patients' tissue samples. : Firstly, MFAP5 expression can be markedly induced under hypoxia condition in HNSCC cell lines. Cell lines with MFAP5 overexpression has a significant higher ability of migration and invasion. In addition, assay observes that overexpression of MFAP5 can promote tumor lung metastasis. Furthermore, MFAP5 facilitates this process by activating epithelial-mesenchymal transition (EMT) program via AKT pathway in HNSCC cell lines. The pro-metastatic effect of MFAP5 can be reversed by MK2206, an AKT phosphorylation inhibitor. Lastly, the positive correlation among HIF-1α, MFAP5 and vimentin from tissue samples and TCGA dataset are also observed in HNSCC. : Our study demonstrates MFAP5 plays a critical role in hypoxia-induced EMT program via AKT pathway in HNSCC, which would be a very promising therapeutic target.
MFAP5 inhibits the malignant progression of endometrial cancer cells .
Liang G, Qi Z, Du C Open Life Sci. 2025; 19(1):20220990.
PMID: 39759103 PMC: 11699556. DOI: 10.1515/biol-2022-0990.
Wang H, Yang L, Chen W, Li K, Xu M, Peng X Front Immunol. 2024; 15:1446613.
PMID: 39524442 PMC: 11543424. DOI: 10.3389/fimmu.2024.1446613.
Li X, Ke Q, Qu A, Wang J, Zhao J, Xu P Mar Biotechnol (NY). 2024; 26(4):741-753.
PMID: 38969905 DOI: 10.1007/s10126-024-10342-8.
Smetanina M, Korolenya V, Sipin F, Oscorbin I, Sevostyanova K, Gavrilov K Biosci Rep. 2024; 44(5).
PMID: 38743016 PMC: 11139664. DOI: 10.1042/BSR20231938.
Du C, Qi Z, Zhang W Curr Pharm Biotechnol. 2024; 26(2):235-245.
PMID: 38415489 DOI: 10.2174/0113892010259632240213091136.